OncRef

Clinical Trial: NCT03462719

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Janssen Research & Development, LLC
Information Provided By:Janssen Research & Development, LLC
Last Update Posted:2026-11-03

Study Overview

Brief Summary

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).

Official Title

A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Intervention / Treatment

  • Drug: Ibrutinib
  • Drug: Venetoclax
  • Drug: Chlorambucil
  • Drug: Obinutuzumab
  • Drug: Ibrutinib (as Subsequent Therapy)

Other Study ID Numbers

  • CR108428
  • 2017-004699-77
  • 54179060CLL3011
  • 2017

Start Date (Actual)

2018-04-17

Primary Completion Date (Actual)

2021-02-26

Study Completion Date (Estimated)

2029-04-05

Enrollment (Actual)

211

Study Type

Interventional

Phase

Phase 3